KPTI News and Press, Karyopharm Therapeutics Inc. From 02/25/19

Karyopharm Therapeutics (NASDAQ: KPTI ) appoints Michael P. Mason as Senior VP, Chief Financial Officer (CFO) and Treasurer. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- Formerly of Alnylam Pharmaceuticals, Praecis Pharmaceuticals, and KPMG; Brings Over 18 Years of Financial Leadership Experience Within the Life Sciences Industry -- NEWTON, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage...

Gainers: Achieve Life Sciences (NASDAQ: ACHV ) +78% . The Trade Desk (NASDAQ: TTD ) +31% . Wayfair (NYSE: W ) +29% . DMC Global (NASDAQ: BOOM ) +29% . Voyager Therapeutics (NASDAQ: VYGR ) +24% . Roku (NASDAQ: ROKU ) +23% . Universal Display (NASDAQ: OLED ) +23% . Zillow Group, Inc....

Karyopharm Therapeutics ( KPTI -39.5% ) is down on a 6x surge in volume following the release of briefing materials for next Tuesday's FDA advisory committee meeting on selinexor tablets (with dexamethasone) in relapsed/refractory multiple myeloma (RRMM). The review team does not ap...

"The combination of selinexor and dexamethasone demonstrated limited efficacy and significant toxicity in patients with relapsed/refractory multiple myelom (RRMM)," concludes the FDA. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more...

NEWTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. Karyopharm's management team will hos...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

NEWTON, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the ...

"Injustice is relatively easy to bear; what stings is justice ." - H.L. Mencken Today, we revisit a promising "Busted IPO" we have not discussed in a couple of months. We revisit this name and talk about some recent events and upcoming potential catalysts in the paragraphs below. Compan...

Never promote someone who hasn't made some bad mistakes, because if you do, you are promoting someone who has never done anything. - Philip Fisher Karyopharm Therapeutics (NASDAQ: KPTI ) is a highly promising cancer medicine innovator. Despite that the stock is trading on a downtrend in ...